PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50123C00021MILE lungpacer medical USA INC — Lungpacer Medical Usa Inc

Lungpacer Medical Usa Inc holds — across 1 federal awards. Competition previously drew 100 offers. Set-aside status: NONE. Recompete timing centers on the Dec 15, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Lungpacer Medical Usa Inc

Recipient

Dec 15, 2027

PoP end

$750K

Obligated

$750K

Potential

541714

NAICS

AN13

PSC

NONE

Set-aside

100 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Lungpacer Medical Usa Inc — $90

Contract facts

NONE

Contract number75A50123C00021

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentLungpacer Medical Usa Inc

CAGE8K9A8

UEIEM2BL19AALM8

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN13

Place of performanceEXTON PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

Related solicitationBAA-20-100-SOL-0002

PoP startMay 1, 2023

PoP end (current)Dec 15, 2027

Obligated$750K

Current value$750K

Potential value$750K

LUNGPACER MEDICAL USA INC LUNG-PROTECTIVE EFFECTS OF TRANSVENOUS DIAPHRAGM ACTIVATION IN PATIENTS WITH ARDS AOI #12: MITIGATING LONG-TERM EFFECTS (MILE) OF RESPIRATORY DISTRESS is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Lungpacer Medical Usa Inc. Estimated value $750K ($750K obligated). Current period of performance ends Dec 15, 2027. Last award drew 100 bidders. Place of performance: EXTON PA. Related solicitation BAA-20-100-SOL-0002.

LUNGPACER MEDICAL USA INC LUNG-PROTECTIVE EFFECTS OF TRANSVENOUS DIAPHRAGM ACTIVATION IN PATIENTS WITH ARDS AOI #12: MITIGATING LONG-TERM EFFECTS (MILE) OF RESPIRATORY DISTRESS

Recompete timing

Public

● Expiring in 482 days

Current PoP ends Dec 15, 2027 (482 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Incumbent footprint

Public record

Lungpacer Medical Usa Inc — — obligated across 1 awards (firm-wide, all agencies).

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50123C00021?

75A50123C00021 (MILE lungpacer medical USA INC) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $750K, currently held by Lungpacer Medical Usa Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50123C00021?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50123C00021 to Lungpacer Medical Usa Inc (potential $750K).

Who is the incumbent on 75A50123C00021?

Lungpacer Medical Usa Inc is the incumbent with — across 1 related awards in SCOUT’s public footprint. The current period of performance ends Dec 15, 2027.

When does Lungpacer Medical Usa Inc’s 75A50123C00021 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 15, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Mar 18, 2026